4732.TWO NatureWise Biotech & Medicals Corporation
- Market cap
- TWD 717M
- P/E
- -
- P/B
- 1.35x
- ROE
- -14.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 4732.TWO undervalued?
Graham numberThe Graham number of NatureWise Biotech & Medicals Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NatureWise Biotech & Medicals Corporation fundamental analysis
No fundamental analysis for NatureWise Biotech & Medicals Corporation yet.
NatureWise Biotech & Medicals Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NatureWise Biotech & Medicals Corporation
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It also sells food and beverages. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products. The company was founded in 1990 and is headquartered in Taipei, Taiwan.
Full company profileNatureWise Biotech & Medicals Corporation financial statements
NatureWise Biotech & Medicals Corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 57.5M | 69.1M | 108M | 307M | 307M | 250M | 229M | 160M | 224M | 177M |
| Gross Profit | 23.4M | 29.6M | 50.3M | 161M | 171M | 135M | 119M | 87.4M | 120M | 85.7M |
| Operating Income | -66.3M | -60.0M | -21.8M | 32.9M | 57.9M | 27.0M | 26.3M | 3.43M | -12.0M | -107M |
| EBITDA | -63.6M | -55.6M | -8.02M | 44.4M | 70.0M | 38.3M | 37.3M | 20.4M | 7.46M | -90.4M |
| Net Income | -60.0M | -60.5M | -14.8M | 39.7M | 65.3M | 30.8M | 30.0M | 10.1M | 897K | -92.3M |
| EPS | -1.62 | -1.63 | -0.40 | 1.05 | 1.32 | 0.62 | 0.61 | 0.20 | 0.02 | -1.91 |
| Balance Sheet | ||||||||||
| Total Assets | 351M | 308M | 306M | 607M | 658M | 705M | 693M | 698M | 841M | 713M |
| Total Liabilities | 11.2M | 29.2M | 42.0M | 73.9M | 59.9M | 80.2M | 51.1M | 64.9M | 57.0M | 72.1M |
| Shareholders' Equity | 339M | 279M | 264M | 533M | 598M | 624M | 642M | 634M | 741M | 624M |
| Cash & Short-term Investments | 259M | 155M | 133M | 403M | 472M | 498M | 494M | 475M | 615M | 97.7M |
| Total Debt | 270K | 297K | 2.88M | 12.2M | 3.83M | 12.6M | 4.99M | 10.7M | 3.77M | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -60.6M | -53.8M | -20.6M | 41.0M | 55.6M | 33.7M | 13.9M | 62.2M | -2.80M | -112M |
| Capital Expenditure | 4.43M | 483K | 1.68M | 2.88M | 2.73M | 176K | 152K | 634K | 143K | 1.38M |
| Free Cash Flow | -65.0M | -54.3M | -22.3M | 38.1M | 77.4M | 28.9M | 17.3M | 61.6M | -2.94M | -113M |
| Ratios | ||||||||||
| ROE | -17.7% | -21.7% | -5.6% | 7.5% | 10.9% | 4.9% | 4.7% | 1.6% | 0.1% | -14.8% |
| ROA | -17.1% | -19.6% | -4.8% | 6.5% | 9.9% | 4.4% | 4.3% | 1.4% | 0.1% | -12.9% |
| Net Profit Margin | -104.3% | -87.5% | -13.7% | 12.9% | 21.3% | 12.3% | 13.1% | 6.3% | 0.4% | -52.2% |
| Debt to Equity | 0.00x | 0.00x | 0.01x | 0.02x | 0.01x | 0.02x | 0.01x | 0.02x | 0.01x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NatureWise Biotech & Medicals Corporation dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 27, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | TWD 9.86M | 0.20 | 1,098.9% |
| 2023 | TWD 24.6M | 0.49 | 243.5% |
| 2022 | TWD 14.8M | 0.30 | 49.3% |
| 2021 | TWD 4.65M | 0.09 | 15.1% |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1060:1000 on Sep 13, 2021.
Who owns NatureWise Biotech & Medicals Corporation
Ownership data of NatureWise Biotech & Medicals Corporation is not available yet.
NatureWise Biotech & Medicals Corporation company profile
- Company name
- NatureWise Biotech & Medicals Corporation
- Ticker
- 4732.TWO
- ISIN
- TW0004732003
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 36, Bade Road, Taipei, Taiwan
- Phone
- 886 2 2570 6300
- Website
- naturewise.com.tw
About NatureWise Biotech & Medicals Corporation
NatureWise Biotech & Medicals Corporation engages in the research and development of Western medicine, Chinese medicine, and biotechnology in Taiwan. It also sells food and beverages. It offers LipoCol Forte, a capsule for hypercholesterolemia and hypertriglyceridemia; and green propolis and red yeast rice products. The company was founded in 1990 and is headquartered in Taipei, Taiwan.
NatureWise Biotech & Medicals Corporation management
5- Zhong Yang HuangChairman & President
- Jun Kai ChenChief Financial Officer and Assistant Vice President
- Yuling YangAccounting Supervisor
- Xing Ling CaiMarketing Manager
- Nian Ci HongTreasurer & Audit Office Manager